foto hpv conference-berlin 2011


27° Conferenza Internazionale e Clinical Workshop sul Papillomavirus.
17 – 22 Settembre 2011: 27° Conferenza Internazionale e Clinical Workshop sul Papillomavirus, Berlino (Germania) A. De Montis, bcs Biotech SpA, Cagliari, ITALY

Cervical cancer is the most common cancer among women in Benin. The aim of this pilot study was to examine the prevalence of high-risk oncogenic Human Papilloma Virus (HPV) types using both L1 and E6/E7region as DNA targets.Methods. 239 women DNA from cervical swabs were evaluated by new biochip platform for the detection of two HPV genomic sequences: L1, 34 types including both oncogenic high (HR) and low (LR) risk types, and E6/E7, nine genetic groups comprising only high-medium risk types. The correlation of genotypes with the cytological results was also evaluated.

Samples tested were: 24 invalids, 108 negative, 107 positive for HPV DNA. Among positive samples, 41 DNA (38%) were positive for E6/E7 sequences of HR HPV types no detectable respect to L1 region. The type were conirmed by sequencing method. The cytological analysis showed that 11 of 41 were High-grade Squamous Intraepithelial Lesion (HSIL), 2 were Low-grade, 13 were Atypical Squamous Cells of Undetermined Signiicance (ASCUS). Among HR virus detectable thanks to L1 speciic probes, HPV-59 genotype was the most frequent, followed in order by HPV-16, HPV-35, HPV-18, and HPV-58. Among HR virus detectable only respect to E6/E7 speciic probe, HPV-35 genotype was the most frequent, followed in order by HPV-16, HPV-58, HPV-52 and HPV-33. The most frequent LR HPV type was HPV-81, followed by HPV-40, HPV-67, HPV-11, and HPV-42. In 10% of samples the LR types were in coinfection with non typable L1 HR HPV.

The data highlighted the importance of seeking also genomic E6/E7 in order to reduce the number of false negatives and to exclude the persistence of undetectable or underdiagnosed HR virus. This pilot study conirmed that in Benin there was a substantial presence of HPV genotypes against which the vaccines available do not show cross-protection eicacy.